Top Markets
#1 Derive Derive +33.59%
#2 Cross Cross +17.56%
#3 The Bitcoin Bull The Bitcoin Bull +14.37%
#4 Audiera Audiera +9.42%
#5 Gama Token Gama Token +9.19%
#6 Geodnet Geodnet +9.10%
#7 Velvet Velvet +8.40%
#8 Biconomy Biconomy +7.55%
#9 Starpower Starpower +7.38%
#10 Based Based +7.36%
Coin of the day
Derive Derive
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
MetaVia Inc. MetaVia Inc.

MetaVia Inc.

MTVA
Classifica tra le azioni #35877
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Prezzo delle azioni
$1.51
Ultima sincronizzazione: 2026-08-14
Capitalizzazione di mercato
$3.32M
Variazione (1 giorno)
3.42%
Variazione (1 anno)
-78.55%
Paese
US
Scambia MetaVia Inc. (MTVA)

Categoria

Healthcare
Storico del prezzo dell'azione per MetaVia Inc. (MTVA)
Prezzo di chiusura più alto: $1.46 il 2026-08-01

Prezzo di chiusura più basso: $27.36 il 2024-11-01
Storico del prezzo dell'azione di MetaVia Inc. dal 2024 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -43.25%
2025 -62.61%
2024 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $505.24 28.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $846.09 29.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 6.47%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.75%
BE